Related references
Note: Only part of the references are listed.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
G. Cavaletti et al.
ANNALS OF ONCOLOGY (2013)
Clinical pattern and associations of oxaliplatin acute neurotoxicity
Andreas A. Argyriou et al.
CANCER (2013)
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients
A. A. Argyriou et al.
ANNALS OF ONCOLOGY (2012)
Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
Cindy S. Tofthagen et al.
CANCER NURSING (2011)
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Guido Cavaletti et al.
LANCET ONCOLOGY (2011)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Richard A. Adams et al.
LANCET ONCOLOGY (2011)
Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
Susanna B. Park et al.
ONCOLOGIST (2011)
Surviving Chemotherapy for Colon Cancer and Living with the Consequences
Cindy Tofthagen
JOURNAL OF PALLIATIVE MEDICINE (2010)
Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms
Anna-Liisa Kautio et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2008)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
Background noise - The experience of chemotherapy-induced peripheral neuropathy
Marie A. Bakitas
NURSING RESEARCH (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives
Mugdha Gore et al.
JOURNAL OF PAIN (2006)
Sleep impairment in patients with painful diabetic peripheral neuropathy
Diane C. Zelman et al.
CLINICAL JOURNAL OF PAIN (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
AA Argyriou et al.
SUPPORTIVE CARE IN CANCER (2006)
Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up
Alberto Pietrangeli et al.
EUROPEAN NEUROLOGY (2006)
Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer
J Choi et al.
ANTI-CANCER DRUGS (2006)
Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep
M Gore et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2005)
Oxaliplatin-induced neurotoxicity and the development of neuropathy
AV Krishnan et al.
MUSCLE & NERVE (2005)
Empirical validation of the insomnia severity index in cancer patients
MH Savard et al.
PSYCHO-ONCOLOGY (2005)
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20
TJ Postma et al.
EUROPEAN JOURNAL OF CANCER (2005)
Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study
L Almadrones et al.
ONCOLOGY NURSING FORUM (2004)
Share Paper
